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Abstract: The process of conversion between AED monotherapies is frequently necessary in epilepsy care, yet little prac-
tical guidance is available to practitioners. This article introduces an issue of Current Neuropharmacology devoted to the 
theme of AED conversions and related issues. In this series of articles, we reviewed the role of AED monotherapy in 
newly diagnosed epilepsy, the practice of transitional polytherapy during AED monotherapy conversions in patients expe-
riencing breakthrough seizures or adverse effects, chronic maintenance polytherapy for refractory epilepsy, and the related 
topics of strategies for minimizing adverse effects, appropriate blood level monitoring, and patient-related factors in AED 
conversions. Successful conversion between AED monotherapies and polytherapy drug sequencing requires that practitio-
ners possess and apply a thorough knowledge of epilepsy, AED pharmacology, and clinical reasoning, while being sensi-
tive and reactive to patient reported adverse effects of treatment. 
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“One thing at a time, all things in succession. That which grows fast, withers as rapidly. That which grows slowly, endures.” 
Dr. Josiah Gilbert Holland, Founder of Scribner’s Monthly 
“When the music changes, so does the dance.” 
African Proverb 
INTRODUCTION 
  The first antiepileptic drug (AED) monotherapy utilized 
successfully manages nearly half of epilepsy patients; how-
ever, conversion to a second monotherapy is necessary for 
those who fail to become seizure-free or who do not tolerate 
an initially chosen AED, and chronic polytherapy is neces-
sary in many patients who develop refractory epilepsy [1].
Over the last two decades, there has been more progress in 
available treatments for epilepsy than any other time in his-
tory. There are now 17 marketed commonly used AEDs, 
eleven of which were approved since 1990. While all newer 
AEDs were first approved in the United States for adjunctive 
treatment of partial-onset seizures—leading to their near-
exclusive use as polytherapy initially—there is now increas-
ing use of newer AEDs as monotherapy paralleling expand-
ing evidence basis for formal approval of monotherapy use, 
and adequate evidence to support off-label monotherapy use. 
Increasing generic availability may further encourage earlier 
use of newer AEDs in both monotherapy and adjunctive 
therapy situations. Given this shifting paradigm in uses of 
newer AEDs from sole polytherapy applications to increas-
ing monotherapy usage, and the practical need to transition 
AEDs in many patients, the subject matter of conversions 
between AED monotherapies is timely.
  Monotherapy is widely favored over polytherapy by neu-
rologists in the treatment of newly diagnosed epilepsy, lim- 
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ited evidence for this “monotherapy maxim” notwithstand-
ing. Abundant evidence is available when initiating adjunc-
tive AED therapy in refractory epilepsy, on practical grounds 
an important setting for use of newer AEDs since when a 
new AED becomes available, it is generally first limited to 
use in refractory patients having the greatest need for im-
proved seizure control, until its safety and tolerability profile 
and expanded evidence for use in other settings is well estab-
lished. While it is probable that all AEDs proven effective in 
adjunctive polytherapy settings are also efficacious for use as 
monotherapy, available evidence guiding AED monotherapy 
remains somewhat limited, leading to relatively narrow FDA 
indications in United States practice. Several newer AEDs 
have randomized controlled trial evidence for monotherapy 
application, while clinical experience and lesser evidence 
lead to FDA “grandfathering” of older AEDs for monother-
apy indication in newly diagnosed epilepsy. However, rela-
tively little evidence is available to guide clinicians as they 
implement changes between monotherapy or polytherapy 
AED regimens for patients with epilepsy. A panel of epi-
lepsy neurologists and clinical pharmacologists was recently 
convened to address this important topic. The goal of the 
SPECTRA panel (Study by a Panel of Experts: Considera-
tions for Therapy Replacement in Antiepileptics) was to de-
velop consensus regarding practical issues in AED mono-
therapy conversions. This panel developed consensus on a 
key overriding treatment principle: to fully titrate an adjunc-
tive drug prior to tapering a baseline drug when possible. 
The panel also developed drug-specific consensus recom-
mendations that expand and complement available prescrib-
ing information that is useful in planning AED monotherapy 76    Current Neuropharmacology, 2009, Vol. 7, No. 2 Erik K. St. Louis 
conversions as well as AED sequencing in chronic polyther-
apy regimens [2]. 
 This  issue  of  Current Neuropharmacology focuses on the 
topic of AED conversions in epilepsy care. This series of 
articles begins with a practical review of AED monotherapy 
in newly diagnosed epilepsy, next examines factors involved 
in monotherapy conversions during the process of transi-
tional polytherapy, then outlines important considerations in 
ensuring successful chronic polytherapy. A discussion of the 
rationale and strategies for minimizing adverse effects in 
epilepsy care is then followed by a review of principles for 
appropriate blood level monitoring. Finally, this issue con-
siders important patient-related factors in AED conversions. 
The above-referenced motivational sentiment of 19
th century 
physician, author, and poet Josiah Holland well anticipated 
the approach to epilepsy treatment favored herein: initiate 
AED treatment as monotherapy, sequence medications as 
needed to achieve seizure control or improve a patient’s ac-
ceptance and tolerability of therapy, and titrate most medica-
tions slowly and carefully to ensure maximal success. How-
ever, as the ensuing proverb reminds us, conversion between 
different AEDs may require specific modifications to ensure 
treatment success. The SPECTRA data summarized herein 
provides clinicians with a helpful new approach to guide 
conversions between AED therapies, and the accompanying 
review articles offer further relevant guidance for clinicians 
implementing AED conversions in epilepsy care. 
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